Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

CVRx misses in Q4, wins FDA approval for new IPG

February 15, 2022 By Jim Hammerand

CVRx Barostim

Barostim Neo [Image from CVRx]

CVRx (NSDQ:CVRX) posted fourth-quarter results today that fell short of the consensus forecast on Wall Street and offered its outlook for the year ahead.

The Brooklyn Park, Minnesota-based neuromodulation implant developer reported a loss of $10.57 million, or $0.52 per diluted share, on sales of $3.7 million for the three months ended Dec. 31, 2021, for a bottom-line loss of 210% and sales growth of 75% compared with Q4 2020.

The loss was $0.08 per share deeper than expected by the Street, where analysts were looking for EPS of -$0.44 on sales of $3.86 million.

Full-year revenue climbed to $13 million, a 115% increase over the year before, but just short of the company’s projection after the third quarter.

The company lost nearly $43.1 million in 2021, compared to a $14.1 million loss in 2020. Significant costs included $27.9 million for selling, general and administrative expenses (up 187%) as the company hires employees and spends on marketing and advertising related to the commercialization of CVRx’s Barostim therapy for heart failure. The company also reported a $13.7 million increase in stock-related expenses, and in November paid $21.3 million to fully repay a $20 million loan from Horizon Technology Finance Corp.

Though the loss grew by total dollar value, when calculated on a per-share basis, it fell from $10.04 in Q4 2020 due to the growth of the number of shares outstanding. CVRx went public with a $126 million IPO in June 2021; the company reported 360,412 shares outstanding around the end of 2020 and nearly 20.4 million at the end of 2021.

CVRx said it expects $3.6 million to $4 million in first-quarter revenue and full-year revenue of $20 million to $23 million in 2022.

CVRx CEO Nadim Yared

CVRx CEO Nadim Yared [Photo courtesy of CVRx]

“We are excited about the position we are in as we move into 2022,” CVRx CEO Nadim Yared said in a news release. “Throughout the year we will be focused on driving accelerated adoption by executing on our commercial strategy, which includes the continued expansion of our salesforce and the efforts to educate healthcare providers and consumers on the benefits of Barostim.”

CVRx won FDA approval for its Barostim Neo system — the first heart failure neuromodulation device — in 2019. The company describes its technology as “designed to electrically activate the baroreflex, the body’s natural mechanism to regulate cardiovascular function.”

More recently, the company won FDA approval in December 2021 for a new, smaller IPG (implantable pulse generator) that the company said will deliver 20% longer battery life.

CVRx expects FDA approval in the first half of 2022 for MRI conditional labeling (allowing magnetic scanning with specific instructions for Barostim patients) and a new programmer to simplify the software in a tablet form.

The company’s early backers included GlaxoSmithKline and Johnson & Johnson, the latter of which remains the largest shareholder.

UPDATE: CVRx stock was trading around $8.33 per share, down about 3%, the day after the company released its financial results.

You may also like:

  • DeviceTalks Weekly
    CVRx CEO Nadim Yared suggests steps toward improving diversity and…

  • CVRx CEO details the path from being engineer to medtech…
  • CVRx CEO Nadim Yared
    CVRx CEO Nadim Yared keeps his edge

Related Articles Read More >

Download COMSOL News Special Edition Biomedical
A variety of tube-to-tube barb connectors
Qosina adds new tube-to-tube barb connectors
A portrait of Keri Mattox, Zimmer Biomet's chief communications and administration officer
Zimmer Biomet adds ESG and CEO visibility to executive’s duties
A portrait of Geoff Martha, CEO of Medtronic
‘Catastrophic explosion’ and resin shortage led Medtronic’s supply chain problems

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech